Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Roger's 1998 Short Picks -- Ignore unavailable to you. Want to Upgrade?

To: poodle who wrote (13961)	9/23/1998 12:03:00 PM
From: Bob Trocchi	Read Replies (2) \| Respond to of 18691

Roger/poodle... Found an article about the biotech industry this a.m. in which HEPH was mentioned. This may be having an upward bias stock price impact today and potentially the remainder of this week. I have only copied the portion of the article that mentions HEPH. FYI >>One tiny California company, Hollis-Eden Pharmaceuticals (HEPH), has seen its shares triple since touching a low on Oct. 27, 1997. Hollis-Eden receives practically no coverage from the investment community. The San Diego company is working on drug combinations for the treatment of AIDS, Hepatitis and organ transplant rejections. Bill Corbett at The Shemano Group in San Francisco says the company's Inactivin interrupts cellular factors, thus inhibiting AIDS' HIV virus from replicating. "The stock is rearing its head," said Corbett on Wednesday. "But it's still really early stage." Shemano Group raised almost $20 million for the company in a private placement. Corbett said Inactivin might begin Phase 1 trials in two months.<< cbs.marketwatch.com